Key PointsAxsome Therapeutics is generating rapid revenue growth from its expanding portfolio of central nervous system treatments.

Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?

(RTTNews) - Axsome Therapeutics, Inc. (AXSM) reported third-quarter 2026 net product revenue of $259.7 million, up 52% from $171.0 million in the prior-year quarter, driven by growth across AUVELITY, SUNOSI and SYMBRAVO. The company also highlighted progress in its neuroscience p

Axsome Therapeutics Q3 Sales Rise Across Key Brands; Pipeline Milestones Set For 2027 

Key PointsAxsome Therapeutics currently demonstrates a stronger revenue profile than Moderna, ultimately surpassing its counterpart in total sales volume for the quarter ended June 2026 despite starting from a considerably lower historical baseline at the very beginning of the ch

Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility

Key PointsAxsome Therapeutics has a deep late-stage pipeline that could eventually lead to much improved financial results.

2 Under-the-Radar Stocks to Buy and Hold

Key PointsAxsome sees at least $8 billion in potential peak Auvelity sales.

Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's?

Key PointsAxsome Therapeutics is seeing massive revenue growth as it expands its footprint in the central nervous system treatment market.

Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics, Inc. News